JaxBio Chip Detects Lung Cancer Signals in Blood Without Sequencing
JaxBio Technologies has published results showing their $60 cfDNA methylation chip can detect lung cancer signals in blood without sequencing. The study appeared in npj Precision Oncology.
JaxBio Technologies has announced peer-reviewed findings demonstrating that its $60 cfDNA methylation chip can detect lung cancer signals in blood samples without requiring DNA sequencing. The study was published in the journal npj Precision Oncology.
The technology employs a hybrid capture method on-chip and an enzyme-based fluorescent labeling technique to profile methylation patterns associated with lung cancer in cell-free DNA (cfDNA). JaxBio suggests this approach offers a faster and more cost-effective alternative for early cancer detection.
According to the study, the chip successfully identified specific cfDNA methylation patterns linked to lung cancer. These alterations are indicative of tumor breakdown and could potentially serve as early biomarkers for cancer presence.
The company intends to move forward with the commercialization of this technology, aiming to provide a more accessible tool for cancer diagnostics. This development could significantly impact the future of lung cancer screening and early detection efforts.